Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Abraham E, Reinhart K, Svoboda P et al. (2001) Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled single-blind, dose escalation study. Crit Care Med 29: 2081–2089
Abraham E, Reinhart K, Opal S et al. (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290/2: 238–247
Acute Respiratory Distress Syndrome Network (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342: 1301–1308
Angus DC, Laterrre P-F, Helterbrand J, Ball D, Garg R, Bernard GR (2003) The effect of drotrecogin α (activated) on long-term survival after severe sepsis. Chest 122(Suppl): S144
Annane D, Sebile V, Charpentier C et al. (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288: 862–871
Bajzar L, Morser J, Nesheim M (1996) TAFI, or plasma carboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 271: 16603–16608
Barie PS (2002) Drotrecogin α (activated) has a favorable benefit/risk profile in surgical patients with severe sepsis. Crit Care Med 30(Suppl 12): A102
Barnes PJ, Karin M (1997) Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066–1071
Bellomo R, Farmer M, Wright C, Parkin G, Boyce N (1995) Treatment of sepsis-associated severe acute renal failure with continuous hemodiafiltration: clinical experience and comparison with conventional dialysis. Blood Purif 13: 246–254
Bernard G (2002) The International Sepsis Forum’s controversies in sepsis: corticosteroids should not be routinely used to treat septic shock. Crit Care 6: 384–386
Bernard GR, Ely EW, Wright TJ et al. (2001) Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 29: 2051–2059
Bernard GR, Macias WL, Vincent JL (2002) Drotrecogin α (activated) cumulative safety update. Chest 122(Suppl): S141
Bernard GR, Vincent JL, Laterre PF et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699–709
Bick RL (2002) Disseminated intravascular coagulation: a review of etiology, pathophysiology, diagnosis and management: guidelines for care. Clin Appl Thromb Hemost 8: 1–31
Bick RL, Arum B, Frenkel EP (1999) Disseminated intravascular coagulation. Clinical and pathophysiological mechanisms and manifestations. Haemostasis 29: 111–134
Blauhut B, Kramar H, Vinazzer H, Bergmann H (1985) Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 39: 81–89
Chiron EC (2002) Chiron announces results of phase III study of tifacogin in severe sepsis. Chiron, Emeryville, USA, Internet Communication, accessed September 6
Corrigan JJ, Ray WL, May N (1968) Changes in the blood coagulation system associated with septicemia. N Engl J Med 279: 851–856
Creasey AA, Reinhart K (2001) Tisue factor pathway inhibitor activity in severe sepsis. Crit Care Med 29(Suppl): S126–S129
Jonge E de, Levi M, Stoutenbeek CP, van Deventer SJ (1998) Current drug treatment strategies for disseminated intravascular coagulation. Drugs 55: 767–777
Eisele B, Lamy M (1998) Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and multiple organ failure. Semin Thromb Hemost 24: 71–80
Ely EW, Baker AM, Dunagan DP et al. (1996) Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. N Engl J Med 335: 1864–1869
Esmon C (2000) The protein pathway. Crit Care Med 28(Suppl): S44–S48
Ettingshausen CE, Veldmann A, Beeg T, Schneider W, Jager G, Kreuz W (1999) Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin Thromb Hemost 25: 537–541
Faust SN, Levin M, Harrison OB et al. (2001) Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345: 408–416
Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J (1993) Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104: 882–888
Fourrier F, Jourdain M, Tournoys A (2000) Clinical trial results with antithrombin III in sepsis. Crit Care Med 28(Suppl): S38–S43
Gando S, Kameue T, Morimoto Y, Matsuda N, Hayakawa M, Kemmotsu O (2002) Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 30: 1729–1734
Gardlund B (2000) Antithrombin therapy of no value in sepsis according to a large clinical trial. Lakartidningen 99: 1456–1460
Grinnell BW, Joyce D (2001) Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. Crit Care Med 29(Suppl): S53–S60
Gross PL, Aird WC (2000) The endothelium and thrombosis. Semin Thromb Hemost 26: 463–478
Hancock WW, Grey ST, Hau L et al. (1995) Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation 60: 1525–1532
Hesselvik JF, Malm J, Dahlback B, Blomback M (1991) Protein C, protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemost 65: 126–129
Iba T, Kidokoro A, Yagi Y (1991) The role of the endothelium in changes in procoagulant activity in sepsis. Thromb Haemost 65: 126–129
Iba T, Yagi Y, Kidokoro A (1998) Protective effects of antithrombin III on organ dysfunction induced by the continuous infusion of endotoxin in rats. J Jpn Assoc Acute Med 9: 45–52
Inthorn D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M (1998) Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock 10: 90–96
Jimenez MF, Marshall JC (2001) Source control in the management of sepsis. Intensive Care Med 27(Suppl 1): S49–S62
Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW (2001) Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 276: 11.199–11.203
a Kujath P, Bouchard R, Heinze I, Thees C, Putensen C (2003) Aktiviertes Protein C, Antithrombin, Heparin und Gewebethromboplastininhibitor: Neue Algorithmen für die Therapie der schweren Sepsis? Intensiv Notfallbeh 28: 44–54
Lasch HG, Krecke H-J, Rodriguez-Erdmann F, Sessner HH, Schütterle G (1961) Verbrauchskoagulopathien (Pathogenese und Therapie). Folia Haematol 6: 325–330
Laterre P-F, Levy H, Bal D, Helterbrand J, Angus DC (2002) The effects of drotrecogin α (activated) on hospital mortality, length of stay, and discharge location. Chest 122(Suppl): S143
Levi M, van der Poll PT, ten Cate H, van Deventer SJ (1997) The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxemia. Eur J Clin Invest 27: 3–9
Marik PE, Zaloga GP (2001) Early enteral nutrition in acutely ill patients: a systematic review. Crit Care Med 29: 2264–2270
Massignon D, Lepape A, Bienvenu J, Barbier Y, Boileau C, Coeur P (1994) Coagulation/fibrinolysis balance in septic shock related to cytokines and clinical state. Haemostasis 24: 36–48
Moalli R, Doyle JM, Tahhan HR, Hasan FM, Braman SS, Saldeen T (1989) Fibrinolysis in critically ill patients. Am Rev Respir Dis 140: 287–293
Morris P, Garber G, Laterre P-F, Levy H (2001) Drotrecogin α (activated) reduced the number of deaths attributed to cardiovascular and pulmonary organ failure in patients with severe sepsis. Crit Care Med 29(Suppl): A11
Müller-Berghaus G, ten Cate H, Levi M (1999) Disseminated intravascular coagulation: clinical spectrum, and established as well as new diagnostic approaches. Thromb Haemost 82: 706–712
Muller FM, Ehrenthal W, Hafner G, Schranz D (1996) Purpura fulminans in severe congenital protein C deficieny: monitoring of treatment with protein C concentrate. Eur J Pediatr 155: 20–25
Okajima K, Uchiba M (1998) The anti-inflammatory properties of antithrombin III: new therapeutic implications. Semin Thromb Hemost 24: 27–32
Pettila V, Hyminen M, Takkunen O, Kuusela P, Valtonen M (2002) Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. Intensive Care Med 28: 1220–1225
Reinhart K, Bayer O, Brunkhorst F, Meisner M (2002) Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 30(Suppl): S302–S312
Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W (2002) Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296: 1880–1882
Rintala E, Kauppila M, Seppala OP et al. (2000) Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med 28: 2373–2378
Rivers E, Nguyen B, Havstad S (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345: 1368–1377
Scherer RU, Pulletz S, Ziemer S, Peters J (2001) Antithrombin-(AT)Wirkung: Experimentelle und klinische Ergebnisse. Anästhesiol Intensivmed Notfallmed Schmerzther 36: 628–639
Smith OP, White B (1999) Infectious purpura fulminans: diagnosis and treatment. Br J Haematol 104: 202–207
Tylor FB Jr (1994) The inflammatoy-coagulant axis in the host response to Gram-negative sepsis: regulatory roles of proteins and inhibitors of tissue factor. New Horiz 2: 555–565
Van den Berghe BG, Wouters P, Weekers F et al. (2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345: 1359–1367
Warren BL, A Eid, Singer P et al. (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286: 1869–1878
Yan SB, Dhainaut JF (2001) Activated protein C vs. protein C in severe sepsis. Crit Care Med 29(Suppl): S69–S74
Yan SB, Helerbrand JD, Hartman DL, Wright TJ, Bernard GR (2001) Low levels of protein C are associated with poor outcome in severe sepsis. Chest 120: 915–922
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Putensen, C., Kujath, P., Bouchard, R., Heinze, I., Thees, C. (2005). Heparin, Antithrombin, Gewebethromboplastin-Inhibitor und aktiviertes Protein C: Stellenwert für die Therapie der schweren Sepsis?. In: Werdan, K., Schuster, HP., Müller-Werdan, U. (eds) Sepsis und MODS. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26587-2_21
Download citation
DOI: https://doi.org/10.1007/3-540-26587-2_21
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-00004-4
Online ISBN: 978-3-540-26587-0
eBook Packages: Medicine (German Language)